NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation
NXT007 enhanced TG capacity of HA plasma <i>in vitro</i> in the coexistence of emicizumab without an abnormal synergistic increase or reduction in coagulation potential, consistent with their competitive antigen binding. These findings suggest that switching from emicizumab to NXT007 can be achieved without emicizumab washout.
Authors
- Takehisa Kitazawa (ORCID: https://orcid.org/0000-0002-4958-7936)
- Keito Inaba
- Hikaru Koga (ORCID: https://orcid.org/0000-0001-9693-5334)
- Kenta Haraya (ORCID: https://orcid.org/0000-0002-9142-5607)
- Kazuki Yamaguchi (ORCID: https://orcid.org/0000-0001-6478-9336)
- Masaru Muraoka (ORCID: https://orcid.org/0000-0002-6559-9785)
- Kei Nishimura
- Atsushi Muto
Institutions
- Chugai Pharma (United States) (US)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.rpth.2025.103236
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00